IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.65
−5.28%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$32.24
From 52W high−27.85%
Volume1.24M
Market cap$2.96B
P/E (TTM)—
P/S (TTM)81.1x
Div yield—
Key dataNov 5, 2026
Open
$32.24
From 52W high
−27.85%
Volume
1.24M
Market cap
$2.96B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.0x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
−5.28%
YTD Return
−10.15%
SummaryUpdated Sep 1, 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company founded in 2015 and headquartered in South San Francisco, California. The company went public in May 2019 and focuses on developing targeted cancer therapeutics using a synthetic lethality approach. IDEAYA identifies specific genetic vulnerabilities in cancer cells and develops drugs that exploit these weaknesses while sparing healthy cells. The company currently has multiple drug candidates in clinical trials and maintains strategic partnerships with major pharmaceutical companies including Pfizer and GlaxoSmithKline.
Similar companies
Latest newsMore news →
IDEAYA Biosciences reported a quarterly loss of $1.22 per share, compared with a loss of $1.26 per share expected and earnings of $1.33 per share a year earlier.3d agoIDEAYA Biosciences, Inc. reported third-quarter 2026 financial results and said it had $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026.3d agoIDEAYA Biosciences, Inc. said it is targeting two Phase 3 registrational trials of IDE849 in extensive-stage small cell lung cancer and neuroendocrine carcinomas following successful Type C meetings with the U.S. FDA.14d ago